Home

MARKSMAN HEALTHCARE COMMUNICATIONS | A DATA SCIENCE COMPANY

In this progressing and increasingly competitive commercial landscape, attaining optimal market access is becoming extra challenging for pharmaceutical/medical device patrons. In the stir of the global economic crisis, ever increasing costs and abating healthcare budgets, payers have a significant and growing influence on a product’s commercial success. The need to demonstrate clinical and economic evidence of a product to providers, healthcare decision-makers and payers is becoming the central component to a product’s success.

MarksMan Healthcare Communications is a Health Economic and Outcomes Research (HEOR), Medical Writing and Data Analytics consulting, committed in providing the highest level of scientific evidence to optimize the value and health impact of medicines and health technologies. We offer customised information solutions for all stages of product’s life-cycle and therapeutic categories. We utilize the expertise of our trained professionals to provide accurate, consistent and concise product, disease and therapeutic area information.

Our experienced and trained analytics team provides HEOR, Real Wold Evidence (RWE) and market access support to large and small life science companies. We further provide services pertaining to “Medical Affairs, Data Curation, Patient Chart Abstraction, Data Analytics, Pharmacovigilance and Regulatory Writing”

OUR SERVICES

A scientific research consulting committed in providing the highest level of scientific evidence to optimize the value and health impact of medicines and health technologies. We offer customised information solutions for all stages of product’s life-cycle and therapeutic categories.

HEOR

Medical Affairs

Data Curation

Patient Registry

Data Analytics

LATEST FROM BLOG

06Dec 2021

Results from over half of all conducted randomized controlled trials (RCTs), especially those with negative or unfavorable results, never get published. This means, searching only electronic databases that index published literature does not provide the entire spectrum of information; additionally, a bias is induced, since most trials having negative results get omitted. This is extremely […]

01Dec 2021

Systematic reviews (SRs) are the embodiment of the evidence-based approaches, and they have reformed clinical decision-making in almost all therapy areas. The approach of SRs was essentially developed to fulfil the need of the medical practitioners to obtain precise and consistent information about the efficacy and safety of a clinical intervention, diagnostic procedure, or a […]

15Nov 2021

Systematic reviews (SRs) often face a major challenge while identifying all the relevant research, including randomised controlled trials (RCTs) irrespective of their publication status.(1) Unpublished, selectively reported, or non-reported research can lead to poorer quality clinical trials, thus leading to suboptimal care delivery. It also overlooks the opportunities for potential scientific progress.(2) Such incomplete publication […]

LATEST PRESENTATIONS

  • ISPOR 23rd Annual Meeting, May 19-23, 2018, Baltimore, USA

    Efficacy and Safety of Everolimus as a Combination Therapy in the Treatment of Metastatic Breast Cancer: A Systemic Review and Meta-analysis

  • ISPOR 23rd Annual Meeting, May 19-23, 2018, Baltimore, USA

    Efficacy and Safety of Vedolizumab in the Treatment of Ulcerative Colitis: A Systemic Review and Meta-analysis

  • DIA 2018 Global Annual Meeting 2018, June 24-28, 2018, Boston, USA

    Role of Social Media in Patient Reported Outcomes (PRO) Research

  • ISPOR 23rd Annual Meeting, May 19-23, 2018, Baltimore, USA

    Efficacy and Safety of Enzalutamide in Metastatic Prostate Cancer Patients: A Systematic Review and Meta-Analysis

  • ISPOR 23rd Annual Meeting, May 19-23, 2018, Baltimore, USA

    Adaptive Licensing and Real World Evidence (RWE)

  • ISPOR 23rd Annual Meeting, May 19-23, 2018, Baltimore, USA

    A Comparison of AMSTAR and ROBIS tools for Methodological Quality Assessment of Systematic reviews of Alzheimer’s Disease

WHAT OUR CLIENT SAY

OUR COLLABORATIONS